|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2009-5-29
|
|
pubmed:abstractText |
With the aim of improving patient selection for phase I trials, we previously performed a retrospective analysis of 212 phase I oncology patients where we were able to develop a prognostic score predicting overall survival (OS). This prospective study was performed to test the validity of the prognostic score.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2692-6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19332724-Adolescent,
pubmed-meshheading:19332724-Adult,
pubmed-meshheading:19332724-Aged,
pubmed-meshheading:19332724-Biological Markers,
pubmed-meshheading:19332724-Clinical Trials, Phase I as Topic,
pubmed-meshheading:19332724-Disease-Free Survival,
pubmed-meshheading:19332724-Female,
pubmed-meshheading:19332724-Health Status Indicators,
pubmed-meshheading:19332724-Humans,
pubmed-meshheading:19332724-Kaplan-Meier Estimate,
pubmed-meshheading:19332724-L-Lactate Dehydrogenase,
pubmed-meshheading:19332724-Male,
pubmed-meshheading:19332724-Middle Aged,
pubmed-meshheading:19332724-Neoplasm Metastasis,
pubmed-meshheading:19332724-Neoplasms,
pubmed-meshheading:19332724-Patient Selection,
pubmed-meshheading:19332724-Predictive Value of Tests,
pubmed-meshheading:19332724-Proportional Hazards Models,
pubmed-meshheading:19332724-Prospective Studies,
pubmed-meshheading:19332724-Reproducibility of Results,
pubmed-meshheading:19332724-Risk Assessment,
pubmed-meshheading:19332724-Serum Albumin,
pubmed-meshheading:19332724-Treatment Outcome,
pubmed-meshheading:19332724-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.
|
|
pubmed:affiliation |
Royal Marsden Hospital and Institute of Cancer Research, Drug Development Unit, Sutton, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Validation Studies
|
